Radiometer: The UK Based Company Announces POCT Analyzers Help Tackle ED Overcrowding with a Faster Diagnoses

Radiometer reports that a new case study shows how point-of-care testing (POCT) involving Radiometer’s blood gas and immunoassay analyzers, has led to faster diagnoses and improved patient experience in the emergency department (ED) at Queen’s Hospital*, Romford.

The study, authored by Clare Bailey, Divisional Director of Healthcare Professionals, Cancer and Clinical Support at Barking, Havering, and Redbridge University Hospitals NHS Trust, shows how Radiometer’s POCT ABL90 FLEX PLUS blood gas analyzers and AQT90 FLEX immunoassay analyzers have enabled the ED team to manage increasing patient numbers and deliver high-quality care.

Commenting on Radiometer’s POCT analyzers, Clare Bailey said: “The benefits of the ABL90 FLEX PLUS blood gas analyzer are clear. It measures urea and blood urea nitrogen (BUN) on very small sample volumes, which helps in the stratification of patients with suspected gastrointestinal bleeding, respiratory infections, or dehydration.

Additionally, it is one of the few POCT instruments on the market that can also measure creatinine and it’s important for our department to have this capability because we can triage our patients more quickly. On top of that, we also have the AQT90 FLEX analyzer, which was a great benefit for the ED staff, because it measures, for example, troponins, D-dimer and CRP – having all three was a real game-changer for us.”

The full case study can be found at https://www.radiometer.co.uk/en-gb/knowledge-center/customer-stories/queens-hospital

*Queen’s Hospital in Romford is part of the Barking, Havering and Redbridge University Hospitals NHS Trust (BHRUT) in London, UK. Clare Bailey is the divisional director of healthcare professionals, cancer and clinical support at the BHRUT.

 

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version